Silence Therapeutics plc
$7.93
▲
8.59%
2026-04-21 09:28:00
www.silence-therapeutics.com
NGM: SLN
Explore Silence Therapeutics plc stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$349.74 M
Current Price
$7.93
52W High / Low
$2.6 / $0.5
Stock P/E
—
Book Value
$1.32
Dividend Yield
—
ROCE
-76.17%
ROE
-90.27%
Face Value
—
EPS
$-1.89
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
88
Beta
1.33
Debt / Equity
0.26
Current Ratio
8.72
Quick Ratio
8.72
Forward P/E
-7.96
Price / Sales
484.17
Enterprise Value
$727 M
EV / EBITDA
-8.89
EV / Revenue
1,300.53
Rating
None
Target Price
$32.8
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | PepGen Inc. | $1.73 | — | $117.5 M | — | -58.05% | -67.39% | $7.8 / $1.01 | $2.14 |
| 2. | Cytokinetics, Incorporated | $65.05 | — | $8.11 B | — | -50.1% | 197.47% | $70.98 / $29.31 | $-5.37 |
| 3. | Eikon Therapeutics, Inc. | $11.55 | — | $644.25 M | — | -62.8% | -1.25% | $17.4 / $8.58 | $-286.47 |
| 4. | Cartesian Therapeutics, Inc. | $6.94 | — | $183.97 M | — | -30.8% | 195.88% | $15.57 / $5.6 | $-4.85 |
| 5. | CytoMed Therapeutics Limited | $1.02 | — | $12.07 M | — | -33.09% | -50.28% | $3.68 / $0.73 | $0.43 |
| 6. | Caris Life Sciences, Inc. | $21.24 | — | $5.98 B | — | 4.52% | -45.37% | $42.5 / $16.28 | $2.04 |
| 7. | Codexis, Inc. | $2.62 | — | $235.35 M | — | -31.3% | -74.88% | $3.87 / $0.96 | $0.56 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.03 M | 0.16 M | 0.22 M | 0.14 M | 24.33 M | — |
| Operating Profit | -12.46 M | -26.24 M | -22.64 M | -28.41 M | -3.08 M | — |
| Net Profit | -11.77 M | -20.96 M | -27.35 M | -28.53 M | 14.17 M | — |
| EPS in Rs | -0.25 | -0.44 | -0.58 | -0.6 | 0.3 | -0.75 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.56 M | 43.26 M | 31.64 M | 21.66 M |
| Operating Profit | -89.75 M | -63.32 M | -64.38 M | -61.04 M |
| Net Profit | -88.61 M | -45.31 M | -54.23 M | -50.33 M |
| EPS in Rs | -1.88 | -0.96 | -1.15 | -1.07 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 131.44 M | 202.63 M | 119.45 M | 130.1 M |
| Total Liabilities | 69.14 M | 68.61 M | 97.45 M | 103.38 M |
| Equity | 62.3 M | 134.02 M | 21.99 M | 26.71 M |
| Current Assets | 118.66 M | 187.37 M | 103.15 M | 117.01 M |
| Current Liabilities | 13.61 M | 16.82 M | 22.34 M | 26.56 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -62.27 M | -67.64 M | -49.46 M | -57.04 M |
| Investing CF | -47.99 M | -21.97 M | 19.29 M | -20.5 M |
| Financing CF | 0.01 M | 142.09 M | 31.94 M | 52.58 M |
| Free CF | -62.33 M | -67.85 M | -49.52 M | -57.59 M |
| Capex | -0.06 M | -0.21 M | -0.06 M | -0.55 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 36.71% | 46.12% | — | — |
| Earnings Growth % | 16.45% | -7.74% | — | — |
| Profit Margin % | -104.74% | -171.37% | -232.44% | — |
| Operating Margin % | -146.38% | -203.47% | -281.87% | — |
| Gross Margin % | 72.7% | 59.34% | 37.83% | — |
| EBITDA Margin % | -145% | -201.5% | -279.12% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.